Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
Condition(s) studied
Investigational drug(s) / intervention(s)
Antiplatelet-only strategy: Aspirin 75-325 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
Oral Anticoagulant plus background antiplatelet therapy: OAC with vitamin K antagonist (VKA) with international normalized ratio (INR) target 2-3 or any approved direct oral anticoagulant OR apixaban, rivaroxaban, edoxaban or dabigatran) in addition to background antiplatelet therapy with aspirin 75-325mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
Study summary
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery.
All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.
Eligibility
Primary outcome measure(s)
- Composite of death, ischemic stroke, TIA, MI, systemic arterial thromboembolism or venous thromboembolism (DVT and/or PE) — up to 180 days after randomization
Composite score of death, ischemic stroke, transient ischemic attack (TIA), myocardial infarction (MI), systemic arterial thromboembolism or venous thromboembolism (deep venous thrombosis and/or pulmonary embolism). Composite score calculated by number of events. - Any BARC type 3 or 5 — 90 days after randomization
The Bleeding Academic Research Consortium (BARC) - any type 3 or 5 bleeding thrombosis and/or pulmonary. Type 3: a. Overt bleeding plus hemoglobin drop of 3 to \< 5 g/dL (provided hemoglobin drop is related to bleed); transfusion with overt bleeding b. Overt bleeding plus hemoglobin drop \< 5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents c. Intracranial hemorrhage confirmed by autopsy, imaging, or lumbar puncture; intraocular bleed compromising vision. type 5: a. Probable fatal bleeding b. Definite fatal bleeding (overt or autopsy or imaging confirmation)
Trial sites (106)
| Facility | City | Region | Status |
|---|---|---|---|
| CHI St. Vincent, Arkansas | Little Rock | Arkansas | Recruiting |
| University of Southern California | Los Angeles | California | Recruiting |
| Cedars-Sinai Medical Center | Los Angeles | California | Recruiting |
| Stanford University | Stanford | California | Recruiting |
| Medical Center of Aurora | Aurora | Colorado | Active Not Recruiting |
| Western Connecticut Hospital Systems | Danbury | Connecticut | Active Not Recruiting |
| Yale Medicine | New Haven | Connecticut | Recruiting |
| MedStar Washington Hospital Center | Washington D.C. | District of Columbia | Recruiting |
| Emory University | Atlanta | Georgia | Recruiting |
| Piedmont Healthcare Inc. | Atlanta | Georgia | Recruiting |
| Lutheran Medical Center | Fort Wayne | Indiana | Active Not Recruiting |
| Indiana University | Indianapolis | Indiana | Active Not Recruiting |
| Ascension St. Vincent | Indianapolis | Indiana | Active Not Recruiting |
| Ochsner Clinic | New Orleans | Louisiana | Recruiting |
| Maine Medical Center | Portland | Maine | Recruiting |
| University of Maryland | Baltimore | Maryland | Recruiting |
| Johns Hopkins | Baltimore | Maryland | Recruiting |
| Suburban Hospital | Bethesda | Maryland | Active Not Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | Recruiting |
| Brigham and Women's Hospital | Boston | Massachusetts | Recruiting |
| Boston Medical Center | Boston | Massachusetts | Active Not Recruiting |
| Baystate Health | Springfield | Massachusetts | Active Not Recruiting |
| University of Michigan | Ann Arbor | Michigan | Recruiting |
| Mayo Clinic | Rochester | Minnesota | Recruiting |
| Mid America Health Institute | Kansas City | Missouri | Recruiting |
| Washington University School of Medicine | St Louis | Missouri | Recruiting |
| Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | Recruiting |
| Jersey Shore University Medical Center | Neptune City | New Jersey | Recruiting |
| Northwell Health System | Great Neck | New York | Recruiting |
| The Mount Sinai Hospital | New York | New York | Withdrawn |
| Columbia University Medical Center | New York | New York | Recruiting |
| Montefiore Medical Center | The Bronx | New York | Recruiting |
| Duke University | Durham | North Carolina | Recruiting |
| East Carolina University | Greenville | North Carolina | Recruiting |
| WakeMed | Raleigh | North Carolina | Withdrawn |
| Cleveland Clinic Foundation | Cleveland | Ohio | Recruiting |
| Ohio State University Medical Center | Columbus | Ohio | Active Not Recruiting |
| Ascension St. John | Tulsa | Oklahoma | Active Not Recruiting |
| University of Pittsburgh Medical Center | Hermitage | Pennsylvania | Withdrawn |
| University of Pennsylvania | Philadelphia | Pennsylvania | Recruiting |
+ 66 more sites — see the full list on the official registry below.
More Icahn School of Medicine at Mount Sinai trials in Canada
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04045665 on ClinicalTrials.gov ↗ ← All trials in Canada